Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey

Overview of attention for article published in Frontiers in oncology, March 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (59th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 10,058 followers.

RT @FrontOncology: 👩‍🔬👨‍⚕️ Real-world #Myeloma data: "Daratumumab as single agent is safe and well-tolerated regimen in real-life, associat…

👩‍🔬👨‍⚕️ Real-world #Myeloma data: "Daratumumab as single agent is safe and well-tolerated regimen in real-life, associated to prolonged PFS and OS in responding patients." #OpenAccess article ➡ https://t.co/GdJr6iDKEP #MyelomaAwarenessMonth #MultipleMyel

New article: Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey https://t.co/HubnQsTql4 #MMSM #MultipleMyeloma #hematology https://t.co/ck3CnPfSFW

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.